Pepdexpepdex
Stack
โ„– 064

Petrelintide

Zealand Pharma's long-acting amylin analog (partnered with Roche). Phase 2 complete, Phase 3 planned for H2 2026. A competing once-weekly amylin analog, not a Novo or Cagrilintide successor.

Fat Loss
Evidence: Moderate

Petrelintide: Zealand Pharma's long-acting amylin analog (partnered with Roche). Phase 2 complete, Phase 3 planned for H2 2026. A competing once-weekly amylin analog, not a Novo or Cagrilintide successor. Petrelintide is Novo Nordisk's next-generation amylin drug, Cagrilintide's successor.

FDA โ“˜
Not approved
WADA
Not banned
Typical dose
Start 0.3 mg weekly
Half-life โ“˜
~10 days (acylated/lipidated)
Route โ“˜
Subcutaneous
Schedule
Once weekly
In plain English

Petrelintide is Novo Nordisk's next-generation amylin drug, Cagrilintide's successor. Same pathway as Cagrilintide but with weekly dosing and stronger receptor binding. In Phase 2/3 trials. Will eventually pair with Semaglutide the way CagriSema does, but as one drug.

Status & legalityWhat do these mean? โ†’
Natty? โ“˜
Not natty
FDA โ“˜
Not approved

Investigational. Developed by Zealand Pharma (partnered with Roche). Phase 2 complete; Phase 3 planned for H2 2026. Not yet approved.

Compounding โ“˜
Investigational

In clinical trials, not yet approved for prescription.

WADA โ“˜
Not listed
Prescribed โ“˜

Trial access only.

Who it's for

  • โ†’Trial participants in obesity studies
  • โ†’Educational reference for the next-generation amylin pathway
  • โ†’Followers of Zealand Pharma's metabolic pipeline

What to expect

  1. Week 1

    Appetite reduction begins. Less GI side effect profile than GLP-1 monotherapy.

  2. Week 4

    First titration step. Weight loss accruing.

  3. Week 8

    Phase 2 endpoint data showed steady cumulative loss.

Looking at Petrelintide? Your next 3 steps

  1. 1Work out your syringe units

    Vial size + BAC water turns into the exact units to draw for Petrelintide.

    Open calculator โ†’
  2. 2See what to stack & monitor

    The companion supplements and the bloodwork worth tracking on this kind of protocol.

    Bloodwork guide โ†’
  3. 3Save it & ask the Coach

    A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.

    Create free account โ†’

How it works (mechanism)

Next-generation amylin analog with stronger receptor binding and weekly dosing. Same pathway as Cagrilintide.

Dosing protocol

Members only

Stacks well with

Members only

Side effects

01Mild nausea
02Reduced appetite
03Constipation
04Generally cleaner profile than GLP-1 monotherapy

When NOT to use

  • โš MTC / MEN-2 history
  • โš Pancreatitis history
  • โš Pregnancy / nursing

Bloodwork to monitor

  • โ€ข Lipid panel
  • โ€ข A1C if metabolic context

Common mistakes

  • โ€ข Treating community-vendor product as trial-grade material
  • โ€ข Titrating too fast
  • โ€ข Expecting Tirzepatide-tier weight loss as monotherapy

What it actually is

Petrelintide is a long-acting amylin analog from Zealand Pharma, partnered with Roche, in development for weight management. It is a direct competitor to cagrilintide rather than a successor: both are weekly amylin analogs pursuing the same pathway, from different companies. Phase 2 is complete and phase 3 was planned for the second half of 2026. It is not approved anywhere.

Amylin is released alongside insulin at every meal and produces satiety through the brainstem, a different route from GLP-1's. Native amylin lasts minutes and aggregates, so making a usable version requires engineering: petrelintide is acylated so it binds albumin and persists for around ten days. The reason there is interest in amylin agonists as monotherapy rather than only as GLP-1 partners is that the early data suggested a gentler gastrointestinal profile and possibly better preservation of lean mass, though neither is established.

Forms, and which is which

Clinical trial supplyThe only lawful route

Phase 2 complete, phase 3 planned. Identity, dose and monitoring are known only here.

Verdict: The only defensible access.

Products sold as petrelintideNothing lawful

No approved product exists to compare against, so identity, potency and sterility cannot be verified.

Verdict: Unverifiable contents outside any lawful route.

CagrilintideThe competitor with more data

Novo Nordisk's amylin analog, further along, with phase 3 data as part of CagriSema.

Verdict: The same pathway with a bigger evidence base.

PramlintideThe approved ancestor

The approved mealtime amylin analog, dosed before every meal with a boxed warning for hypoglycaemia with insulin.

Verdict: The approved version of this pathway, with a heavier regimen.

What it is claimed to do, graded

Weight loss as amylin monotherapyModerate

Phase 2 is complete with reported weight reduction. One randomised-trial record and one human-trial record are indexed, so the published base is still thin relative to the attention.

Gentler gastrointestinal profile than GLP-1 monotherapyLimited

Suggested in early data and part of the investment case for amylin agonists. No head-to-head trial establishes it.

Better preservation of lean massNone shown

A frequently repeated claim about the amylin class. Not established for this compound.

Safe for long-term useNone shown

Phase 3 has not run. Nothing establishes durability or long-term safety.

Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.

Pros and cons

Pros
  • โ€ข A different mechanism from the GLP-1 drugs, so it is not a fourth version of the same thing
  • โ€ข Weekly dosing
  • โ€ข Amylin biology is well understood, with an approved ancestor in pramlintide
  • โ€ข Phase 2 complete with a phase 3 programme planned, so real evidence is coming
Cons
  • โ€ข Not approved anywhere; access is trial-only
  • โ€ข One indexed randomised-trial record โ€” the published base is much thinner than the coverage suggests
  • โ€ข The tolerability and lean-mass claims that make it interesting are the ones not yet established
  • โ€ข Nothing sold outside a trial can be verified
  • โ€ข Behind cagrilintide in development

When to stop

  • โ€ข Severe persistent abdominal pain radiating to the back
  • โ€ข Vomiting that prevents keeping fluids down
  • โ€ข Hypoglycaemic episodes if you take glucose-lowering medication
  • โ€ข Pregnancy

Interactions

Insulin or sulfonylureasCaution

Amylin analogs slow gastric emptying and reduce food intake; the approved ancestor pramlintide carries a boxed warning for severe hypoglycaemia with insulin for exactly this reason.

Other amylin analogs (cagrilintide, pramlintide)Avoid

Same mechanism, duplicated.

GLP-1 receptor agonistsMonitor

Different pathways, and combining them is what the CagriSema programme tested. Not established for this compound.

Oral medications generallyMonitor

Delayed gastric emptying can alter absorption rate. No approved interaction labelling exists.

Resistance training and adequate proteinCompatible

General weight-loss guidance, not a petrelintide trial finding.

Is this for you?

Probably worth reading further if
  • โ€ข Participation in an authorised clinical trial is the only context in which this is lawfully available
  • โ€ข Anyone following where the amylin class is heading
Skip it if
  • โ€ข You want an approved medicine
  • โ€ข You are pregnant or nursing
  • โ€ข You are treating phase 2 results as a finished evidence base
  • โ€ข Note what is NOT listed here: the thyroid C-cell warning belongs to the GLP-1 class, and carrying it across to an amylin analog would be borrowing a warning that does not apply

The one number

Phase 2 complete with 1 indexed randomised-trial record; phase 3 planned and not yet run
Pepdex evidence index โ€” counts are indexed PubMed records, not deduplicated trials; J Med Chem 2025 (PMID 41217931)

Sources for the claims above

  • Development of petrelintide, a potent long-acting human amylin analogue
    J Med Chem, 2025
  • Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
    Peptides, 2026
  • Dual amylin and calcitonin receptor agonist development context
    J Med Chem, 2025

Drug & supplement interactions

  • โš Same amylin-class precaution: oral medication absorption may be affected
  • โš Trial-only
Free, no account needed

New to Petrelintide? Grab the starter checklist.

Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.

No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.

AI Coach, live sample
Member answer
is 250mcg of bpc enough for a knee injury?
For a knee, is the standard working dose and a solid place to start. The trick with BPC is consistency, give it weeks, not days. , run it , and don't drop below , results tend to fall off under that line. If nothing's moved by week 3, that's when earns its place.
how much bac water for a 10mg reta vial?
is the standard play for a 10 mg reta vial. That gives you , clean unit math across the whole titration: on a 100-unit insulin syringe. Run instead if you want fewer, more concentrated shots. Most people titrate up over , and that mix keeps the numbers cleanest.
what should i track on bloodwork for tirzepatide?
Lipid panel, ALT/AST (liver enzymes), and an A1C, baseline before you start then every 3 months. If you've got metabolic-syndrome history, add fasting glucose and insulin so you can actually watch insulin sensitivity improve. You don't need a big hormone panel for a GLP-1.

Numbers redacted in this preview. Members get the full answer, on their own stack.

Ask the Coach anything about Petrelintide or your own stack. This is it working.

Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.

Unlock the full Coach, from $4.99/week โ†’

Frequently asked

What is Petrelintide?+
Petrelintide is Novo Nordisk's next-generation amylin drug, Cagrilintide's successor. Same pathway as Cagrilintide but with weekly dosing and stronger receptor binding. In Phase 2/3 trials. Will eventually pair with Semaglutide the way CagriSema does, but as one drug.
Is Petrelintide FDA approved?+
Investigational. Developed by Zealand Pharma (partnered with Roche). Phase 2 complete; Phase 3 planned for H2 2026. Not yet approved.
Is Petrelintide legal?+
Petrelintide is not FDA-approved, so there is no approved prescription version. Most supply is sold as "research only" by peptide vendors. A compounding pharmacy may only use substances the FDA permits for compounding, and many research peptides are not permitted โ€” do not assume a compounded prescription is available. Possession is generally not criminalized but distribution without authorization may be. Verify local laws.
Is Petrelintide banned by WADA?+
Petrelintide is not currently on the WADA prohibited list.
Are you still natty after taking Petrelintide?+
No. Petrelintide is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Petrelintide?+
Trial access only.
What's the typical dose of Petrelintide?+
Dosing depends on your goal, experience, and tolerance. The full Petrelintide protocol (dose, frequency, and how to titrate) is in the members section on the entry page.
What are the side effects of Petrelintide?+
Common side effects include: Mild nausea; Reduced appetite; Constipation; Generally cleaner profile than GLP-1 monotherapy. Less common effects and full safety details are on the entry page.
How long until Petrelintide starts working?+
Appetite reduction begins. Less GI side effect profile than GLP-1 monotherapy.
What can you stack with Petrelintide?+
Petrelintide is commonly combined with complementary compounds. The full stacking protocol (what to pair, dosing, and timing) is in the members section on the entry page.
Where do people get Petrelintide?+
Pepdex does not sell, ship, or recommend suppliers. Petrelintide is not FDA-approved; prescription versions require licensed clinical care, and "research only" markets carry real legal and quality risks. /coa explains how to verify a Certificate of Analysis and /guides/scam-vendor-spotting covers the red flags.

Common questions about Petrelintide

Tracked alongside Petrelintide

Same goal, different aisle โ€” each graded on its own evidence in the Pepdex catalog.

Whey protein โ†’
muscle preservation is the open question on any GLP-1 run
Electrolytes โ†’
appetite suppression cuts fluid and sodium intake with it
Fiber โ†’
the constipation answer that shows up in every GLP-1 thread
Metformin โ†’
the prescription neighbour people compare these protocols against

More in Fat Loss

โ„– 009
Tirzepatide

Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.

โ„– 010
Semaglutide

The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.

โ„– 003
Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

โ„– 059
Liraglutide (Saxenda / Victoza)

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.